While olaparib did not seem promising in this diverse group of cancer patients, it did show significant responses in BRCA1‐mutation carriers, due to the synthetic lethal combination of PARP inhibition and BRCA1‐deficiency (Ledermann et al, 2012, 2014). Here, BRCA1 is linked to cancer.